Tobacco

Research Update

Varenicline and Bupropion: Soaring Again With EAGLES?

Topics: Addiction | Addiction Treatment | Bupropion | Chantix | Co-occurring disorders | Dual diagnosis | FDA Warnings | Medication | Pharmacology | Research | Research Update | Side Effects | Smoking Cessation | Smoking Cessation Agents | Substance Use | Substance use disorders | Suicidality | Suicide | Tobacco | Varenicline | Wellbutrin

Review of: Anthenelli RM et al, Lancet 2016;387(10037):2507–2520 Varenicline (Chantix) and bupropion (Zyban and others) are effective treatments for tobacco use disorder, but their use (and sales) took a big hit in 2009 when the FDA slapped both with black box warnings linking them to psychiatric complications, including suicidal ideation. Although

Read More
News of Note

The FDA Campaigns Against Flavored Tobacco Products

Topics: eCigarettes | Free Articles | Smoking Cessation | Tobacco | Vaping

Electronic cigarette use, or vaping, is becoming increasingly common. Companies manufacturing e-cigarettes advertise them as alternatives to conventional cigarettes and even a pathway to smoking cessation. However, the popularity of vaping has sky-rocketed in high schools across the country with adolescents becoming addicted to nicotine daily. Monitorin

Read More